Document Detail

Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors.
MedLine Citation:
PMID:  18520954     Owner:  NLM     Status:  MEDLINE    
Cardiovascular (CV) risk factors, primarily arterial hypertension, modify the structural and functional features of the myocardium and the blood vessels, a process known as CV remodeling. Cardiac remodeling refers to changes in left ventricular (LV) geometry, such as concentric LV geometry and LV hypertrophy (LVH), an independent hallmark of CV risk. Vascular remodeling consists of structural changes of the arterial walls, such as increased intima-media thickness, arterial stiffening, and deteriorating endothelial function. CV remodeling is to a large extent a result of compensatory mechanisms, and its pathophysiology is partially mediated by the activation of the renin-angiotensin-aldosterone system and its primary effector peptide angiotensin II, which together play a key role in the progression of CV disease. Angiotensin-converting enzyme (ACE) inhibitors, a class of drugs used in the treatment of arterial hypertension, appear to be effective in controlling or even reversing CV remodeling, independently of simple blood pressure reduction. Evidence shows that ACE inhibitors counteract CV remodeling by reducing LV mass and regressing LVH, attenuating vascular atherosclerosis and improving vascular compliance. ACE inhibitors possessing a sulfhydryl moiety appear to have additional benefits in increasing nitric-oxide release and improving vascular endothelial function.
Maurizio Galderisi; Oreste de Divitiis
Related Documents :
3281474 - Effect of a converting-enzyme inhibitor on vasa recta blood flow in rat kidney.
6282024 - Fluctuations in the plasma angiotensin i converting enzyme activity during long-term tr...
11208754 - Vascular effects of ace inhibition independent of the renin-angiotensin system in hyper...
12410854 - Renal damage associated with proteinuria.
22936794 - Association of systolic and diastolic blood pressure and all cause mortality in people ...
8268624 - Rescue from pediatric ecmo with prolonged hybrid intratracheal pulmonary ventilation. a...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  51     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-06-24     Completed Date:  2008-10-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  523-31     Citation Subset:  IM    
Division of Cardioangiology with CCU, Department of Clinical and Experimental Medicine, Federico II University Hospital, Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Angiotensin-Converting Enzyme Inhibitors / pharmacology,  therapeutic use*
Body Size
Cardiovascular Diseases / drug therapy*,  physiopathology*
Coronary Vessels / drug effects,  physiopathology
Hemodynamics / drug effects
Hypertension / complications,  physiopathology
Muscle, Smooth, Vascular / drug effects,  physiopathology
Renin-Angiotensin System / drug effects
Risk Factors
Sex Factors
Ventricular Remodeling / drug effects*
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fe...
Next Document:  Structural and diffusion tensor imaging of the fornix in childhood- and adolescent-onset schizophren...